Table 1.
Comparison of characteristics of patients with ICC in high- or low risk groups
| Characteristics | n (%) | No. of patients (%) | Pvalue | ||
|---|---|---|---|---|---|
| High-risk group | Low-risk group | ||||
| Gender | Male | 44 (69.8) | 19 (65.5) | 25 (73.5) | 0.490 |
| Female | 19 (30.2) | 10 (34.5) | 9 (26.5) | ||
| Age (years) | <50 | 23 (36.5) | 12 (41.4) | 11 (32.4) | 0.458 |
| ≥50 | 40 (63.5) | 17 (58.6) | 23 (67.6) | ||
| ALT (U/L) | ≤40 | 48 (76.2) | 24 (82.8) | 24 (70.6) | 0.258 |
| >40 | 15 (23.8) | 5 (17.2) | 10 (29.4) | ||
| AST (U/L) | ≤45 | 55 (87.3) | 26 (89.7) | 29 (85.3) | 0.716 |
| >45 | 8 (12.7) | 3 (10.3) | 5 (14.7) | ||
| TBIL (mmol/L) | ≤20.5 | 54 (85.7) | 27 (93.1) | 27 (79.4) | 0.160 |
| >20.5 | 9 (14.3) | 2 (6.9) | 7 (20.6) | ||
| HBsAg | Negative | 35 (55.6) | 17 (58.6) | 18 (52.9) | 0.651 |
| Positive | 28 (44.4) | 12 (41.4) | 16 (47.1) | ||
| AFP (ng/mL) | ≤25 | 59 (93.7) | 26 (89.7) | 33 (97.1) | 0.326 |
| >25 | 4 (6.3) | 3 (10.3) | 1 (2.9) | ||
| CA199 (U/L) | ≤35 | 27 (42.9) | 11 (37.9) | 16 (47.1) | 0.466 |
| >35 | 36 (57.1) | 18 (62.1) | 18 (52.9) | ||
| CEA (ng/mL) | ≤5 | 46 (73.0) | 19 (65.5) | 27 (79.4) | 0.216 |
| >5 | 17 (27.0) | 10 (34.5) | 7 (20.6) | ||
| Cirrhosis | Yes | 20 (31.7) | 10 (34.5) | 10 (29.4) | 0.666 |
| No | 43 (68.3) | 19 (65.5) | 24 (70.6) | ||
| Histological grade | I + II | 26 (41.3) | 12 (41.4) | 14 (41.2) | 0.987 |
| III | 37 (58.7) | 17 (58.6) | 20 (58.8) | ||
| T stage | T1 | 35 (55.6) | 16 (55.2) | 19 (55.9) | 0.630 |
| T2a | 5 (7.9) | 1 (3.4) | 4 (11.8) | ||
| T2b | 17 (27.0) | 9 (31.0) | 8 (23.5) | ||
| T3 | 6 (9.5) | 3 (10.3) | 3 (8.8) | ||
| N stage | N0 | 44 (69.8) | 17 (58.6) | 27 (79.4) | 0.073 |
| N1 | 19 (30.2) | 12 (41.4) | 7 (20.6) | ||
| TNM stage | I + II | 38 (60.3) | 14 (48.3) | 24 (70.6) | 0.071 |
| III + IV | 25 (39.7) | 15 (51.7) | 10 (29.4) | ||
ALT, alanine aminotransferase; AST, aspartate aminotransferase; TBIL, total bilirubin; HBsAg, hepatitis B surface antigen; AFP, alpha-fetoprotein; CA19-9, carbohydrate antigen 19–9; CEA, carcinoembryonic antigen.